苯达莫司汀
氧化磷酸化
癌症研究
药理学
癌细胞
化学
糖酵解
谷氨酰胺分解
线粒体呼吸链
呼吸链
瓦博格效应
线粒体
抗霉素A
生物化学
癌症
柠檬酸循环
细胞培养
细胞周期
淋巴瘤
联合疗法
生物
作用机理
新陈代谢
细胞
细胞外
代谢途径
作者
Emiri O. Takaki,Yuya Hidoh,Yutaka Obuchi,Yoko Nagai,Shingo Nishikori,Yuki Kuniyoshi,Yasuhiro Sawai,Naoto Ohi
摘要
BACKGROUND AND PURPOSE: Cancer cells exhibit the Warburg effect, but oxidative phosphorylation (OXPHOS) is also important for cancer cell proliferation. Metabolic reprogramming from glycolysis to OXPHOS is one mechanism of resistance to anti-tumour drugs. Here, we have synthesized and characterized OPB-111077, a novel, first-in-class orally available small-molecule compound, and investigated its anti-tumour activity and therapeutic potential in combination with alkylating agents. EXPERIMENTAL APPROACH: Inhibition of mitochondrial function by OPB-111077 were assessed by measuring the oxygen consumption rate, ATP production and Complex I enzymatic activity. anti-tumour effects were evaluated in human haematological and solid tumour cell lines and in cell line-derived xenograft and lymphoma patient-derived xenograft models. Mechanistic studies included CRISPR screening, metabolomic analyses, and measurements of the oxygen consumption and extracellular acidification rates. Effects of OPB-111077 combined with alkylating agents were also assessed in mice. KEY RESULTS: OPB-111077 inhibited mitochondrial respiratory chain Complex I, suppressed OXPHOS, and exerted anti-tumour effects in several models. OPB-111077 demonstrated synergism with the alkylating agent bendamustine, with simultaneous inhibition of both OXPHOS and glycolysis. Bendamustine reprogrammed cancer cells into an OXPHOS-dominant state, thereby enhancing the efficacy of OPB-111077. CONCLUSION AND IMPLICATIONS: Based on these findings, we propose a novel anticancer therapeutic strategy of combining OXPHOS inhibitors with alkylating agents. OPB-111077 has demonstrated potential in combination therapy and was recently evaluated with bendamustine and rituximab in a Phase 1 clinical trial for patients with relapsed/refractory diffuse large B-cell lymphoma (NCT04049825).
科研通智能强力驱动
Strongly Powered by AbleSci AI